ESMO: Obesity Does Not Interfere with Trastuzumab Response, Vall d’Hebron University Hospital Study

MedPageToday -- MILAN -- Obesity is known to be a risk factor for breast cancer and death in postmenopausal women -- but a small study found that obesity does not seem to hamper the response to trastuzumab (Herceptin) therapy in women with metastatic breast cancer.

MORE ON THIS TOPIC